Video

Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma

David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

The CheckMate-143 trial is the first to show maturing data of the efficacy of checkpoint inhibitors in patients with recurrent GBM, with cohorts that examined nivolumab monotherapy as well as nivolumab combined with ipilimumab. In the combination cohort, dosage was 3 mg/kg of ipilimumab and 1 mg/kg of nivolumab. However, patients in the combination arm had a fair amount of grade 3/4 toxicities, Reardon added.

Following these reports, the study was amended to have an adjusted dosing schedule of 1 mg/kg of ipilimumab and 3 mg/kg of nivolumab. Results showed that the safety profile of the adjusted schedule was significantly improved, Reardon said.

<<<

View more from the 2016 ASCO Annual Meeting

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie